Baxter Win Gives Drugmakers A Leg Up In NJ Warning Suits

Law360, New York (August 27, 2012, 8:44 PM EDT) -- A New Jersey federal judge ruled last week that a woman's doctor would have prescribed her a Baxter Healthcare Corp. drug even if a warning label described its clotting risks in more detail, handing drugmakers an important victory in an undeveloped area of law in the pharma-heavy state, attorneys say.

Plaintiff Evageline Baker received Baxter-made heparin, an anti-clotting drug, as part of treatment for a triple coronary bypass. She soon developed heparin-induced thrombocytopenia and thrombosis, or HITT, suffering blood clots and gangrene in one of her...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

BAKER v. APP PHARMACEUTICALS, LLC et al


Case Number

3:09-cv-05725

Court

New Jersey

Nature of Suit

Personal Inj. Prod. Liability

Judge

Joel A. Pisano

Date Filed

November 9, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.